Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

Rhea-AI Summary

Conduit Pharmaceuticals (NASDAQ: CDT) has secured a composition of matter patent from the Korean Intellectual Property Office (KIPO) for AZD1656, its lead asset targeting autoimmune diseases. The Glucokinase Activator's patent approval in South Korea follows recent grants in the U.S., Japan, and Australia, strengthening the company's global intellectual property position. This strategic milestone is particularly significant as South Korea is often commercially partnered with Japan in licensing and distribution arrangements by major Western pharmaceutical companies, enhancing Conduit's presence in the valuable Asia-Pacific pharmaceutical market.

Positive

• Patent approval in South Korea strengthens global IP protection for lead asset AZD1656
• Strategic expansion into Asia-Pacific pharmaceutical market through Korean patent
• Growing international patent portfolio including US, Japan, and Australia enhances potential licensing opportunities

Negative

• None.

• Conduit secures a composition of matter patent from the Korean Intellectual Property Office for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships.
  

NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 09, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals", "Conduit" or the “Company”) today announces that the Korean Intellectual Property Office (KIPO) has granted the composition of matter patent for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune diseases. This approval follows recent grants in the U.S., Japan and Australia and further strengthens Conduit's global intellectual property position as it advances out-licensing discussions. Notably, South Korea is often commercially partnered with Japan in licensing and distribution arrangements by major Western pharmaceutical companies, making this an important strategic milestone in expanding Conduit’s reach across a highly valuable Asia-Pacific pharmaceutical region.

“The approval from the Korean Intellectual Property Office represents another key milestone in our IP strategy,” said Dr. Andrew Regan, Chief Executive Officer of Conduit Pharmaceuticals. “With growing international patent coverage for AZD1656, we are continuing to build a strong foundation for global partnerships and long-term value creation.”

About Conduit Pharmaceuticals

Conduit is a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development. Conduit both acquires and funds the development of Phase 2-ready assets, building an integrated and advanced platform-driven approach powered by artificial intelligence (AI) and cybernetics, and seeking an exit through third-party license deals following successful clinical trials. Led by a highly experienced team of executives including Dr. Andrew Regan and Dr. Freda Lewis-Hall, this novel approach is a departure from the traditional pharma/biotech business model of taking assets through regulatory approval.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding Conduit's future results of operations and financial position, Conduit's business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the inability to maintain the listing of Conduit's securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that Conduit's product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that Conduit may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties to be identified in the proxy statement/prospectus (as amended and supplemented) relating to the business combination completed in September 2023, including those under "Risk Factors" therein, and in other filings made by Conduit with the U.S. Securities and Exchange Commission. Moreover, Conduit operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond Conduit's control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Conduit assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Conduit gives no assurance that it will achieve its expectations.

Investors & Media:
info@conduitpharma.com 

FAQ

What is the significance of CDT's Korean patent approval for AZD1656?

The Korean patent approval strengthens Conduit Pharmaceuticals' global IP position and provides strategic access to the Asia-Pacific pharmaceutical market, as South Korea often partners with Japan in licensing and distribution arrangements.

In which countries does Conduit Pharmaceuticals (CDT) now hold patents for AZD1656?

Conduit Pharmaceuticals holds patents for AZD1656 in South Korea, the United States, Japan, and Australia.

What is AZD1656 and what is it designed to treat?

AZD1656 is a Glucokinase Activator that is being developed to target autoimmune diseases.

How does the Korean patent approval benefit Conduit Pharmaceuticals' business strategy?

The approval enhances Conduit's ability to pursue global partnerships, particularly in the Asia-Pacific region, and supports long-term value creation through potential licensing opportunities.